Related Experiment Video

Updated: Aug 30, 2025

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

1.8K

Integration of PARP-inhibitors in ovarian cancer therapy

Antonella Pietragalla1, Francesca Ciccarone1, Camilla Nero1

  • 1Scientific Directorate, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.

Exploration of Targeted Anti-Tumor Therapy
|September 1, 2022
PubMed

Insights

Poly-ADP-ribose polymerase inhibitors (PARP-I) offer a promising new treatment for ovarian cancer (OC). Clinical trials show PARP-I drugs significantly advance the management of this aggressive disease.

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • Poly-ADP-ribose polymerase inhibitors (PARP-I) are a novel class of targeted therapies.
  • Ovarian cancer (OC) remains an aggressive malignancy with significant unmet needs, particularly in relapsed and advanced stages.

Purpose of the Study:

  • To review and present clinical data on PARP inhibitors in ovarian cancer.
  • To highlight the evidence supporting the regulatory approval of PARP-I in OC patients.

Main Methods:

  • Review of clinical trial data, focusing on Phase II and III studies.
  • Analysis of treatment outcomes and efficacy of approved and investigational PARP-I.

Main Results:

  • Three oral PARP inhibitors (olaparib, niraparib, rucaparib) are currently approved for OC treatment.
  • Two additional PARP-I (veliparib, talazoparib) are under active clinical investigation.
  • PARP-I have demonstrated significant clinical benefits, changing the management landscape of OC.

Conclusions:

  • PARP inhibitors represent a major therapeutic advance in ovarian cancer.
  • The clinical data underscore the efficacy and importance of PARP-I in managing OC patients.
  • Continued research and clinical exploration of PARP-I are crucial for further improving outcomes.
Keywords:
BRCA1 and 2DNA repairPARP-inhibitorshomologous recombination deficiencyovarian cancer

More Related Videos

Evaluating In Vitro DNA Damage Using Comet Assay10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

38.0K
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K